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Abstract. Optical mammography is a functional imaging technique that uses near-infrared light to produce three-
dimensional breast images of tissue oxygen saturation and hemoglobin concentration. It has been used to monitor
the response to neoadjuvant chemotherapy in breast cancer patients. We present the first results on monitoring
tumor response to hormone therapy using optical mammography. We present three case studies from postmeno-
pausal women treated with neoadjuvant hormone therapy for locally advanced breast cancer. The women were
scanned before starting treatment, once during treatment, and then before surgery. Changes in physiological and
optical properties within the tumor and in the rest of the breast were evaluated. At the time of surgery, two patients
partially responded to treatment and one did not respond. The patients that partially responded on ultrasound
revealed a corresponding recovery to normal in the hemoglobin concentration images, whereas the nonresponder
indicated an increase in hemoglobin concentration in the tumor compared to her pretreatment images. These case
studies suggest that optical imaging of the breast during neoadjuvant hormone treatment can provide potentially
valuable information, and that physiological changes within the tumor can be seen in response to treatment. © The
Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part
requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.18.5.056012]
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1 Introduction
1.1 Background
Clinical studies on diffuse optical imaging (DOI) and diffuse
optical spectroscopy (DOS) of breast disease have been appear-
ing in the literature over the last 20 years.1–5 The total hemo-
globin concentration ([HbT]) of malignant tumors is about
three times that for healthy breast tissue (65 34 versus
21 6 μM).6 There is no reported significant difference in tissue
oxygen saturation (SatO2) (66% 24% versus 67% 6%).6
However, not all tumors develop chronic hypoxia, and differences
between the tumor and the background tissue may be lost when
all tumors are averaged together, as reduced SatO2 is seen in some
breast tumors.7–9
1.2 Primary Medical Endocrine Therapy
Primary medical therapy describes chemotherapy and hormone
therapy administered presurgically. It was introduced in the
1970s to shrink inoperable breast tumors in an attempt to make
them operable by mastectomy or breast-conserving surgery.10
Although primary medical therapy does not increase overall sur-
vival, it does increase the likelihood of successful breast-
conserving surgery.11–13
Recently, neoadjuvant hormone therapy has become a popu-
lar treatment option for women with estrogen receptor–positive
(ERþ) tumors, especially in women who may not tolerate
the toxic effects of chemotherapy.14 More than 75% of breast
tumors have an overproliferation of ERs.15 When estrogen
binds to the ERs, pathways that enhance cell proliferation are
activated.16 Letrozole (trade name Femara) is commonly used
to treat postmenopausal women with ERþ tumors, by blocking
estrogen production. This reduces cell proliferation, slows or
stops tumor growth, and causes tumor shrinkage.17
1.3 Optical Imaging of Treatment Response
Reports on the use of DOS and DOI to assess response to
primary medical therapy have been appearing in the literature
since 2004.18 Significant papers have been published by the
Beckman Laser Institute at University of California Irvine,18
the Biomedical Optics group at Dartmouth College,19,20 the
University of Connecticut,21,22 Massachusetts General Hospital
Optical Imaging Lab,23 the University of Toronto,24 and the
University of Pennsylvania Biomedical Optics Group,25,26
among others. Several reviews of the topic have also been pub-
lished.27,28 All published papers to date have been on patients
treated with neoadjuvant chemotherapy, with no publications
examining the response to hormone therapy. In this paper,
we present the results of repeat optical scans performed on
patients undergoing neoadjuvant hormone therapy for locally
advanced breast cancer. We anticipated that optical imaging of
the response to hormone therapy would reveal a slower response
time than chemotherapy (where optical changes have been seen
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days after the start of treatment28), as the median response time
to letrozole treatment on MRI is around 9 weeks.29 Classic
chemotherapy drugs act on the DNA of all rapidly dividing
cells, not just cancer cells. Hormone therapy will only cause
a response in cells that have a particular receptor (in this
case estrogen).30 Estrogen also plays a role in the regulation
of vascular endothelial growth factor and new blood vessel
growth, so blocking its action will have a direct effect on the
vasculature of the tumor. Therefore, any changes seen in
[HbT] are likely to be caused by the treatment.31
2 Method
2.1 Patients
Suitable patients were identified from among women attend-
ing Guy’s and St Thomas’ NHS Foundation Trust and the
Lewisham Hospital NHS Trust (UK). Three women with ERþ
tumors to be treated with neoadjuvant letrozole gave informed
consent to take part in this study. Primary hormone therapy is
generally offered to postmenopausal women if the tumor is
expected to respond to the treatment or if they are too ill to tol-
erate chemotherapy.32 The women presented here were three of
27 women who had been recruited for a larger project.
The study was approved by the University College London
(UCL) Research Ethics Committee and Guy’s Hospital
Research and Development Department. Patients were offered a
modest honorarium for taking part, and transport costs were
reimbursed.
2.2 Imaging Protocol
The UCL time-resolved optical imaging system33 is used to
transmit light to and from the patient breast via a liquid-coupled
patient interface.9,34 The patient lies prone with her breast
pendant in the liquid-coupled patient interface. The system is
described in detail elsewhere,33 but in summary, picosecond
laser pulses at 780 and 815 nm are transmitted to the breast
via 31 optical fibers. Photons transmitted through the breast are
collected by optical fiber bundles coupled to microchannel-
plate photomultiplier tubes that produce an electronic pulse
for each detected photon. A histogram of photon arrival times,
known as a temporal point spread function (TPSF), is generated
for each source-detector combination by timing electronics
(Becker & Hickl, Berlin, Germany). Images are reconstructed
using the intensity and mean flight-time data types extracted
from the TPSFs.34
Patients underwent three optical imaging sessions. The first
scan was before the start of treatment. A second scan was per-
formed halfway through treatment, and the third scan on com-
pletion of treatment, before surgery. Each scan took 3 min, and
both breasts were scanned.
2.3 Image Reconstruction and Analysis
Three-dimensional (3-D) images of scatter (μ 0S) and absorption
(μa) coefficients were reconstructed using the time-resolved
optical absorption and scattering tomography reconstruction
package developed at UCL.9,35 We assume that the optical
absorption represented in the absorption images is due to three
components: oxyhemoglobin (HbO2), deoxyhemoglobin (Hb),
and a background component with the same absorption coeffi-
cient at both wavelengths (assumed to be due to lipid, water,
proteins, and other absorbers).36 The background component
was assumed to contribute 70% of the total absorption, based
on previous findings.9 The combination of absorption data at
two wavelengths and knowledge of the appropriate extinction
coefficients are used to derive [HbT] and SatO2.
A two-dimensional (2-D) coronal slice was extracted from
each 3-D μa, μ 0S, [HbT], and SatO2 reconstructed image at
the location where the lesion contrast was maximal. A circular
tumor region of interest (ROI) was selected around the peak con-
trast in the 2-D image. A second ROI was manually selected as
background breast tissue (excluding the tumor ROI and the cou-
pling fluid). The mean and standard deviation (SD) of the optical
and physiological values within each ROI were calculated. An
equivalent breast ROI from the contralateral breast was also ana-
lyzed. The changes within the tumor and the rest of the breast
were evaluated during the course of therapy.
The statistical differences between measurements, e.g.,
tumor and healthy breast tissue at the start of treatment, were
calculated using a two-tailed t-test with P ≤ 0.001 taken as sig-
nificant. The degrees of freedom for the t-test were calculated
from the number of resolution elements in the image. The spatial
resolution for the optical images was taken from previous
work.36–38 The full-volume half-maximum for 3-D images
was calculated from phantom studies and varies from 10 to
40 cm3 (Ref. 36). We took 20 cm3 as a suitable midrange esti-
mate. From this, we calculated that the equivalent full-width
half-maximum as 16 mm.37 The number of resolution elements
of the image was calculated by dividing the area of the ROI by
the area of one resolution element (¼π.82 mm2). This gives us
the number of resolution elements for the ROI (both tumor and
breast regions), which was taken to be the number of degrees of
freedom for the t-test. This approach has weaknesses (e.g., the
FWMH varies across the image) but gives a reasonable estimate
of the number of degrees of freedom. It is unreasonable to
assume that every pixel in the image is an independent meas-
urement, as each pixel is very closely related to its neighbors.38
3 Results
3.1 Patient A
Patient A is a 66-year-old woman with a grade II carcinoma in
the upper outer quadrant of her right breast. The tumor size was
recorded on clinical notes as 60 by 40 mm using 2-D ultrasound.
Ten weeks after the start of treatment, the lesion measured 34 by
27 mm on ultrasound. On treatment completion, the lesion was
3 mm on ultrasound, indicating a partial response to treatment.
Figure 1 shows the changes in the mean [HbT] in the lesion
and the background tissue over time. The tumor [HbT] was 36
6 μM before treatment, and shrank to 33 4 μM by week 10
and 20.7 0.4 μM by week 15 of treatment. Background breast
tissue [HbT] and contralateral breast tissue [HbT] remained
relatively stable at 21 3 μM. The lesion was hypoxic at the
beginning of treatment at 64% 2% SatO2 versus 70% 2%
in the breast (P ≤ 0.001). The lesion SatO2 rose over the course
of treatment to 69.4% 0.5%, while the background SatO2
remained constant at 69% 3% (P ¼ 0.76).
3.2 Patient B
Patient B is a 64-year-old woman with a grade 1 carcinoma in
the upper inner quadrant of her right breast. Before treatment,
the tumor was 19 by 18 by 20 mm on MRI. The patient was
operated on after 15 weeks of treatment due to lack of response
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on ultrasound, with the tumor measuring 32 by 20 mm on ultra-
sound before surgery. She had an 18-mm grade 1 carcinoma
removed and was classified as not having responded to
treatment.
Figure 2 shows the changes in the mean [HbT] in the lesion
and the background tissue over time. Before treatment, there
was increased [HbT] in the region of tumor compared to the
rest of the breast (30 1 versus 21 3 μM). There was a reduc-
tion in the tumor [HbT] at week 4 to 14.3 0.5 μM,
followed by a large increase in tumor [HbT] to 45 3 μM
compared to the breast [HbT] of 23 6 μM by week 14.
Background breast tissue [HbT] and contralateral breast tissue
[HbT] remained stable at around 22 2 μM. There the tumor
was hypoxic compared to the rest of the breast at the start of
Fig. 1 Mean and standard deviation (SD) total hemoglobin concentration ([HbT]) of the tumor region of interest (ROI) (solid line), healthy background
tissue in the affected breast (dashed line), and tissue of the contralateral breast (dotted line) over time in patient A. There is a significant difference
between the tumor and the background tissue at week 0 (P ≤ 0.001). The background [HbT] remains constant, while the tumor [HbT] decreases by
57% over the course of treatment to equal that of the background. At the end of treatment, there was no significant difference between the tumor and
the background (P ¼ 0.79). A two-dimensional (2-D) slice of the three-dimensional (3-D) [HbT] image is shown for each of the three scans. An
increased region of [HbT] concentration can be seen on the right of the images from scans 1 and 2. *P ≤ 0.001.
Fig. 2 Mean and SD [HbT] of the tumor ROI (solid line), healthy background tissue in the affected breast (dashed line), and tissue of the contralateral
breast (dotted line) over time in patient B. There is a significant difference between the tumor and the background tissue at week 0 (P ≤ 0.001). The
background [HbT] remains constant, while the tumor [HbT] increases by 60% over the course of treatment. At the end of treatment, there was a
significant difference between the tumor and the background (P ≤ 0.001). A 2-D slice of the 3-D [HbT] image is shown for each scan. An increased
region of [HbT] concentration can be seen in the upper inner quadrant. There is also an artifact seen in the first and second scans in the lower inner
quadrant. *P ≤ 0.001.
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treatment (62% 1%) versus (69% 1%) (P ≤ 0.001), which
resolved by week 4 (P ¼ 0.5). In the images, a region of
increased [HbT] can be seen in the upper inner quadrant, in the
region of the tumor in all three images. An area of artifact can
also be seen in the lower inner sector of the image.
3.3 Patient C
Patient C is a 73-year-old woman with a grade 1 carcinoma in
the upper inner quadrant of her left breast. Before treatment, the
tumor was recorded on clinical notes as measuring 15 mm on
mammography and ultrasound. At the time of surgery, a 10-mm
tumor (on pathology) was removed, and the patient was classi-
fied as having a partial response to treatment.
Figure 3 shows the changes in the mean [HbT] in the lesion
and the background tissue over time. There was a significant
difference between the tumor and background [HbT] throughout
the study (P ≤ 0.001). The tumor [HbT] was 30 4 μM before
treatment, falling to 25.2 0.4 μM by week 6 and remaining
constant at 26 1 μM by week 22 of treatment. Background
breast tissue [HbT] and contralateral breast tissue [HbT]
remained stable at 19 2 μM. The tumor showed a significant
increase in tissue SatO2 at the beginning of treatment of 74%
2% compared to 69% 1% in the rest of the breast (P ≤ 0.001).
At the end of treatment, there was no longer a significant differ-
ence between tumor SatO2 and that of the rest of the breast
64% 1% (P ¼ 0.84).
4 Discussion
We have imaged three women being treated with hormone
therapy for locally advanced breast cancer, with the longest
study taking place over 20 weeks. All three women were imaged
three times, resulting in nine useable data sets. All three patients
showed changes in both optical and physiological properties
compared to the rest of the breast in the region of the tumor
(location confirmed by MRI, ultrasound, or mammography) in
their baseline optical scans. For every patient, the physiological
results from their final optical images strongly correlated with
the clinical assessment of response to treatment.
When the background [HbT] levels are compared to pub-
lished data for postmenopausal women, the average values
are slightly higher, with all three women having a background
[HbT] between 19 and 22 μM compared to the published bulk
average values ∼14 μM.6 The observed maximum [HbT] for
tumors at the start of treatment ranged from 30 to 38 μM,
which is at the lower end of the range in the literature (average
½HbT ¼ 65 34 μM).6 All three patients had lower histologi-
cal grade tumors, which may be the reason for the lower tumor
[HbT] compared to the previously published values. It has been
shown that greater microvessel density is linked to more aggres-
sive disease in breast cancer.39
For patient A, the [HbT] in the region of the tumor returned
to baseline at the end of treatment. On ultrasound, she was
classified as a partial responder to treatment, and at surgery,
only 3 mm of tumor tissue was removed. A decrease in tumor
[HbT] was observed in the optical images at 10 weeks into
treatment.
Patient B was operated on early in her proposed treatment
plan due to a lack of response to therapy, and a similar lack
of response was seen on her optical scan conducted at 15
weeks of treatment. However, there was a decrease in tumor
[HbT] seen 4 weeks into therapy. This dip in [HbT] (and in
absorption at both wavelengths) followed by an increase sug-
gests that optically measured early changes in the tumor region
following treatment may not always correlate with final out-
come, as has been shown in patients treated with chemo-
therapy.40,41 An area of artifact was also seen in this image,
and care was taken not to include this region in the image analy-
sis, to avoid introducing errors to the calculated values.
One possible reason for this decrease and then increase in
tumor [HbT] may be the clonal nature of malignant tumors.
When a tumor has reached a size that can be detected on
x-ray imaging, the original cancer cell has already undergone
numerous cell divisions and reached a mass of 108 cells.42
Fig. 3 Mean and SD [HbT] of the tumor ROI (solid line), healthy background tissue in the affected breast (dashed line), and tissue of the contralateral
breast (dotted line) over time in patient C. There is a significant difference between the tumor and the background tissue at week 0 (P ≤ 0.001). The
background [HbT] remains constant, while the tumor [HbT] decreases by 20% by week 10 of treatment. At the end of treatment, there was a significant
difference between the tumor and the background (P ≤ 0.001). A 2-D slice of the 3-D [HbT] image is shown for each scan. An increased region of
[HbT] concentration can be seen in the region of the tumor. *P ≤ 0.001.
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In this mass, there will be cells that are resistant to treatment, or a
certain form of treatment (such as a particular chemotherapy
drug), owing to genetic mutations.43 The initial phase of treat-
ment will kill the cells that are not resistant to treatment, leading
to an initial decrease in tumor mass, followed by an increase as
the treatment-resistant cells continue to proliferate.
Patient C had a partial response to treatment as classified by
ultrasound. A similar decrease in tumor [HbT] was observed in
the optical images and physiological data acquired 6 weeks after
the start of treatment.
In conclusion, we present three case studies on monitoring
patients treated with neoadjuvant letrozole for locally advanced
breast cancer with 3-D optical mammography. This is the first
paper published on monitoring tumor response to endocrine
therapy using optical tomography. Optical imaging results dur-
ing treatment have shown a strong correlation with treatment
outcome. Optical mammography is a promising technique for
monitoring the response to hormone therapy and may provide
valuable physiological information that could be used as an
early predictor of nonresponders and potentially have applica-
tions in drug development.
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